{"id":26555,"date":"2025-06-24T14:52:58","date_gmt":"2025-06-24T11:52:58","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/analize-fara-categorie\/prosigna-pam-50-test-genetic-de-prognostic-in-cancer-de-san\/"},"modified":"2026-07-02T12:32:17","modified_gmt":"2026-07-02T09:32:17","slug":"prosigna-pam-50-test-genetic-de-prognostic-in-cancer-de-san","status":"publish","type":"product","link":"https:\/\/www.clinica-sante.com\/ro\/analize-oncogenetica\/prosigna-pam-50-test-genetic-de-prognostic-in-cancer-de-san\/","title":{"rendered":"Prosigna PAM 50 (Test genetic de prognostic in cancer de san)"},"content":{"rendered":"

Prosigna PAM50<\/strong> este un test genomic validat clinic, utilizat pentru evaluarea riscului de recidiv\u0103 \u00een cancerul de s\u00e2n precoce HR+\/HER2-<\/strong>, prin analiza expresiei a 50 de gene (PAM50).<\/p>\n

Testul clasific\u0103 tumora \u00een unul dintre cele 4 subtipuri moleculare:<\/h3>\n
    \n
  • Luminal A<\/li>\n
  • Luminal B<\/li>\n
  • HER2-enriched<\/li>\n
  • Basal-like<\/li>\n<\/ul>\n

    \u0219i calculeaz\u0103 un Risk of Recurrence Score (ROR)<\/strong>, care estimeaz\u0103 probabilitatea de recidiv\u0103 la distan\u021b\u0103.<\/p>\n

    Analiza ofer\u0103 informa\u021bii despre:<\/h3>\n
      \n
    • agresivitatea biologic\u0103 a tumorii,<\/li>\n
    • riscul de recidiv\u0103 pe termen lung,<\/li>\n
    • beneficiul poten\u021bial al chimioterapiei adjuvante,<\/li>\n
    • stratificarea pacientelor pentru tratament personalizat.<\/li>\n<\/ul>\n

      Indica\u021bii de testare<\/h3>\n
        \n
      • Cancer de s\u00e2n invaziv HR+\/HER2- \u00een stadiu incipient<\/li>\n
      • Decizie privind necesitatea chimioterapiei adjuvante<\/li>\n
      • Evaluarea riscului de recidiv\u0103 dup\u0103 interven\u021bie chirurgical\u0103<\/li>\n
      • Tumori f\u0103r\u0103 indica\u021bie clar\u0103 de tratament sistemic<\/li>\n
      • Stratificare prognostic\u0103 \u00een cancerul mamar precoce<\/li>\n
      • Medicin\u0103 personalizat\u0103 \u00een oncologia s\u00e2nului<\/li>\n<\/ul>\n

        Cui se adreseaz\u0103<\/h3>\n
          \n
        • Pacientelor cu cancer de s\u00e2n precoce<\/li>\n
        • Medicilor oncologi medicali<\/li>\n
        • Chirurgilor oncologi<\/li>\n
        • Tumor boardurilor multidisciplinare<\/li>\n
        • Centrelor de oncologie de precizie<\/li>\n<\/ul>\n

          Metodologie de testare<\/h3>\n
            \n
          • Prelevare \u021besut tumoral FFPE<\/li>\n
          • Microdisec\u021bie pentru selec\u021bia ariei tumorale (dac\u0103 este necesar)<\/li>\n
          • Extrac\u021bie ARN din \u021besut fixat<\/li>\n<\/ul>\n

            Analiz\u0103 de expresie genic\u0103 PAM50 (NanoString \/ RT-PCR echivalent)<\/h3>\n
              \n
            • Calcul scor ROR (Risk of Recurrence)<\/li>\n
            • Clasificare molecular\u0103 \u00een subtipuri intrinseci<\/li>\n
            • Control de calitate al materialului biologic<\/li>\n<\/ul>\n

              Beneficii \u0219i importan\u021b\u0103 clinic\u0103<\/h3>\n
                \n
              • Estimeaz\u0103 riscul individual de recidiv\u0103<\/li>\n
              • Ajut\u0103 la evitarea chimioterapiei inutile<\/li>\n
              • Sprijin\u0103 decizia de tratament personalizat<\/li>\n
              • Ofer\u0103 clasificare molecular\u0103 a tumorii<\/li>\n
              • Optimizeaz\u0103 strategia terapeutic\u0103 \u00een cancerul de s\u00e2n<\/li>\n
              • Reduce supratratamentul sau subtratamentul<\/strong> oncologic<\/li>\n
              • \u00cembun\u0103t\u0103\u021be\u0219te prognosticul prin selec\u021bie terapeutic\u0103 corect\u0103<\/li>\n<\/ul>\n

                Analize asociate recomandate<\/h3>\n

                Profil oncologic complementar<\/h3>\n
                  \n
                • ER \/ PR \/ HER2 imunohistochimie<\/li>\n
                • Ki-67 proliferativ<\/li>\n
                • BRCA1\/BRCA2 (germinal sau somatic)<\/li>\n
                • PIK3CA muta\u021bii<\/li>\n
                • ESR1 muta\u021bii (\u00een recidiv\u0103\/metastatic)<\/li>\n<\/ul>\n

                  Alte teste prognostice oncologice<\/h3>\n
                    \n
                  • Oncotype DX (unde este disponibil)<\/li>\n
                  • MSI \/ MMR status<\/li>\n
                  • TMB (tumor mutational burden)<\/li>\n
                  • PD-L1 imunohistochimie<\/li>\n<\/ul>\n

                    Evaluare clinic\u0103<\/h3>\n
                      \n
                    • Stadializare TNM<\/li>\n
                    • Imagistic\u0103 (RMN\/CT\/PET-CT)<\/li>\n
                    • Status ganglionar<\/li>\n<\/ul>\n

                      Prob\u0103 recoltat\u0103 \/ condi\u021bii analiz\u0103<\/h3>\n

                      \u021aesut tumoral fixat \u00een formalin\u0103 \u0219i inclus la parafin\u0103 (FFPE)<\/h3>\n
                        \n
                      • Bloc tumoral sau lame histologice<\/li>\n
                      • Procent tumoral adecvat confirmat de anatomopatolog<\/li>\n
                      • Transport la temperatura camerei<\/li>\n
                      • Evitarea degrad\u0103rii ARN-ului<\/li>\n<\/ul>\n

                        Documente necesare<\/h3>\n
                          \n
                        • Buletin histopatologic<\/li>\n
                        • Date clinico-patologice (stadiu, ER\/PR\/HER2)<\/li>\n
                        • Recomandare oncologic\u0103<\/li>\n
                        • Informa\u021bii despre tratament planificat sau administrat<\/li>\n<\/ul>\n

                          Denumiri alternative (rom\u00e2n\u0103)<\/h3>\n
                            \n
                          • Test genetic PAM50 \u00een cancerul de s\u00e2n<\/li>\n
                          • Profil genomic de prognostic cancer mamar<\/li>\n
                          • Test de risc de recidiv\u0103 cancer s\u00e2n Prosigna<\/li>\n
                          • Analiz\u0103 expresie genic\u0103 tumoral\u0103 PAM50<\/li>\n
                          • Test molecular prognostic cancer mamar precoce<\/li>\n
                          • Scor genomic de recidiv\u0103 cancer s\u00e2n<\/li>\n
                          • Test de stratificare molecular\u0103 \u00een cancerul de s\u00e2n<\/li>\n
                          • Profil genetic tumoral mam\u0103 (PAM50)<\/li>\n
                          • Test de agresivitate tumoral\u0103 mamar\u0103<\/li>\n
                          • Analiz\u0103 genomic\u0103 prognostic\u0103 cancer s\u00e2n<\/li>\n<\/ul>\n

                            Particularit\u0103\u021bi ale testului<\/h3>\n

                            Prosigna PAM50 este un test de prognostic molecular validat clinic<\/strong>, utilizat pentru stratificarea riscului de recidiv\u0103 \u00een cancerul de s\u00e2n hormonodependent precoce. Integreaz\u0103 expresia genic\u0103 tumoral\u0103 \u00eentr-un scor numeric care sprijin\u0103 decizia terapeutic\u0103 privind necesitatea chimioterapiei adjuvante.<\/p>\n","protected":false},"excerpt":{"rendered":"

                            Analiz\u0103 molecular\u0103 de prognostic pentru cancerul de s\u00e2n hormonodependent (HR+)<\/strong>, bazat\u0103 pe semn\u0103tura genic\u0103 PAM50<\/strong>, care clasific\u0103 tumora \u00een subtipuri biologice \u0219i estimeaz\u0103 riscul de recidiv\u0103 la 10 ani.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[1209,3165,2876],"product_tag":[],"class_list":["post-26555","product","type-product","status-publish","product_cat-analize","product_cat-oncogenetica","product_cat-serviciu-laborator","first","instock","sale","virtual","purchasable","product-type-simple"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t